In other Viking Therapeutics news, CEO Brian Lian sold 194,490 shares of Viking Therapeutics stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $42.75 ...

Viking Therapeutics (NASDAQ:VKTX – Free Report) had its target price lowered by Maxim Group from $120.00 to $70.00 in a research note issued to investors on Friday morning,Benzinga reports.

Reasons to buy Viking Therapeutics now It's hard to overstate the commercial success of drugs that reduce appetites by acting on glucagon-like peptide-1 (GLP-1) receptors.

Shares of Viking Therapeutics have fallen by more than half since the stock peaked early last year. Viking Therapeutics is developing a drug that might be able to outperform today's most popular ...

Nearly a year ago, Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results from a clinical trial with an experimental weight loss ...

Truist lowered the firm’s price target on Viking Therapeutics (VKTX) to $95 from $120 and keeps a Buy rating on the shares. The company’s Q4 update narrowed the timeline for the start of two ...

B. Riley lowered the firm’s price target on Viking Therapeutics (VKTX) to $96 from $109 and keeps a Buy rating on the shares. The firm remains a buyer on share weakness following the Q4 report.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...